Anthony Mascia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anthony Mascia has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- John Peter Perentesis
Division of Oncology Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
4 shared publications - Mathieu Sertorio
Department of Radiation Oncology, University of Cincinnati College of Medicine
4 shared publications - Charles B. Simone
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publications - Jennifer Woo
Varian, a Siemens Healthineers Company, Palo Alto, CA, USA
2 shared publications - John Breneman
Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital, Cincinnati, Ohio
2 shared publications John P. Perentesis
Cancer and Blood Disease Institute, Cincinnati Children's Hospital, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
2 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 222, 111671
FAST-02: Results from the second in-human prospective evaluation of single-fraction proton FLASH for symptomatic thoracic bone metastases
- 24 June 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 222, 111671
Open AccessFAST-02: Results from the second in-human prospective evaluation of single-fraction proton FLASH for symptomatic thoracic bone metastases
- Open Access
- 19 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
The potential and risks of FLASH radiotherapy in pediatric patients
Irradiation at ultra-high dose rates, also termed as ‘FLASH’ radiotherapy, has generated great interest in radiation oncology due to its potential to preferentially spare healthy tissue without compromising tumor control. Over the past decade, studies on the potential benefits of FLASH radiotherapy (FLASH-RT) have grown rapidly, yet the underlying mechanisms of this differential effect remain poorly understood. Nonetheless, compelling preclinical data, particularly the preservation of cognitive function after whole-brain irradiation, suggest that FLASH-RT may significantly improve quality of life, especially for pediatric patients. Early preclinical (large animal) and adult clinical trials are underway, prompting consideration of how and when to translate this modality to pediatric populations. This review summarizes the current state of FLASH-RT, with a special focus on pediatric CNS applications. We discuss disease-specific opportunities and limitations, how biological and clinical differences between adults and children may influence the FLASH effect, and key factors that must be evaluated before safe and effective pediatric translation.
- 19 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Open AccessThe potential and risks of FLASH radiotherapy in pediatric patients
Irradiation at ultra-high dose rates, also termed as ‘FLASH’ radiotherapy, has generated great interest in radiation oncology due to its potential to preferentially spare healthy tissue without compromising tumor control. Over the past decade, studies on the potential benefits of FLASH radiotherapy (FLASH-RT) have grown rapidly, yet the underlying mechanisms of this differential effect remain poorly understood. Nonetheless, compelling preclinical data, particularly the preservation of cognitive function after whole-brain irradiation, suggest that FLASH-RT may significantly improve quality of life, especially for pediatric patients. Early preclinical (large animal) and adult clinical trials are underway, prompting consideration of how and when to translate this modality to pediatric populations. This review summarizes the current state of FLASH-RT, with a special focus on pediatric CNS applications. We discuss disease-specific opportunities and limitations, how biological and clinical differences between adults and children may influence the FLASH effect, and key factors that must be evaluated before safe and effective pediatric translation.
- Open Access
- 17 September 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 56, 101046
In vitro determination of patient-specific variation challenges the universal RBE gold standard for proton radiation therapy
- 17 September 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 56, 101046
Open AccessIn vitro determination of patient-specific variation challenges the universal RBE gold standard for proton radiation therapy
- Top Cited PapersOpen Access
- 5 January 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e41812
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study
Background: In preclinical studies, FLASH therapy, in which radiation delivered at ultrahigh dose rates of ≥40 Gy per second, has been shown to cause less injury to normal tissues than radiotherapy delivered at conventional dose rates. This paper describes the protocol for the first-in-human clinical investigation of proton FLASH therapy. Objective: FAST-01 is a prospective, single-center trial designed to assess the workflow feasibility, toxicity, and efficacy of FLASH therapy for the treatment of painful bone metastases in the extremities. Methods: Following informed consent, 10 subjects aged ≥18 years with up to 3 painful bone metastases in the extremities (excluding the feet, hands, and wrists) will be enrolled. A treatment field selected from a predefined library of plans with fixed field sizes (from 7.5 cm × 7.5 cm up to 7.5 cm × 20 cm) will be used for treatment. Subjects will receive 8 Gy of radiation in a single fraction—a well-established palliative regimen evaluated in prior investigations using conventional dose rate photon radiotherapy. A FLASH-enabled Varian ProBeam proton therapy unit will be used to deliver treatment to the target volume at a dose rate of ≥40 Gy per second, using the plateau (transmission) portion of the proton beam. After treatment, subjects will be assessed for pain response as well as any adverse effects of FLASH radiation. The primary end points include assessing the workflow feasibility and toxicity of FLASH treatment. The secondary end point is pain response at the treated site(s), as measured by patient-reported pain scores, the use of pain medication, and any flare in bone pain after treatment. The results will be compared to those reported historically for conventional dose rate photon radiotherapy, using the same radiation dose and fractionation. Results: FAST-01 opened to enrollment on November 3, 2020. Initial results are expected to be published in 2022. Conclusions: The results of this investigation will contribute to further developing and optimizing the FLASH-enabled ProBeam proton therapy system workflow. The pain response and toxicity data acquired in our study will provide a greater understanding of FLASH treatment effects on tumor responses and normal tissue toxicities, and they will inform future FLASH trial designs. Trial Registration: : ClinicalTrials.gov NCT04592887; http://clinicaltrials.gov/ct2/show/NCT04592887 International Registered Report Identifier (IRRID): DERR1-10.2196/41812
- 5 January 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e41812
Top Cited PapersOpen AccessFLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study
Background: In preclinical studies, FLASH therapy, in which radiation delivered at ultrahigh dose rates of ≥40 Gy per second, has been shown to cause less injury to normal tissues than radiotherapy delivered at conventional dose rates. This paper describes the protocol for the first-in-human clinical investigation of proton FLASH therapy. Objective: FAST-01 is a prospective, single-center trial designed to assess the workflow feasibility, toxicity, and efficacy of FLASH therapy for the treatment of painful bone metastases in the extremities. Methods: Following informed consent, 10 subjects aged ≥18 years with up to 3 painful bone metastases in the extremities (excluding the feet, hands, and wrists) will be enrolled. A treatment field selected from a predefined library of plans with fixed field sizes (from 7.5 cm × 7.5 cm up to 7.5 cm × 20 cm) will be used for treatment. Subjects will receive 8 Gy of radiation in a single fraction—a well-established palliative regimen evaluated in prior investigations using conventional dose rate photon radiotherapy. A FLASH-enabled Varian ProBeam proton therapy unit will be used to deliver treatment to the target volume at a dose rate of ≥40 Gy per second, using the plateau (transmission) portion of the proton beam. After treatment, subjects will be assessed for pain response as well as any adverse effects of FLASH radiation. The primary end points include assessing the workflow feasibility and toxicity of FLASH treatment. The secondary end point is pain response at the treated site(s), as measured by patient-reported pain scores, the use of pain medication, and any flare in bone pain after treatment. The results will be compared to those reported historically for conventional dose rate photon radiotherapy, using the same radiation dose and fractionation. Results: FAST-01 opened to enrollment on November 3, 2020. Initial results are expected to be published in 2022. Conclusions: The results of this investigation will contribute to further developing and optimizing the FLASH-enabled ProBeam proton therapy system workflow. The pain response and toxicity data acquired in our study will provide a greater understanding of FLASH treatment effects on tumor responses and normal tissue toxicities, and they will inform future FLASH trial designs. Trial Registration: : ClinicalTrials.gov NCT04592887; http://clinicaltrials.gov/ct2/show/NCT04592887 International Registered Report Identifier (IRRID): DERR1-10.2196/41812
- 1 November 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 84 (3) , S492-S493
A Comparative and Dosimetric Analysis Regarding the Practical Use of 3D Conformal, IMRT, VMAT, and Proton Therapy for the Treatment of Early-Stage T1/T2 Glottic Laryngeal Cancer
- 1 November 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 84 (3) , S492-S493
A Comparative and Dosimetric Analysis Regarding the Practical Use of 3D Conformal, IMRT, VMAT, and Proton Therapy for the Treatment of Early-Stage T1/T2 Glottic Laryngeal Cancer